VPM
ORMP icon

Vanguard Portfolio Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Vanguard Portfolio Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
+229,882
New +$915K ﹤0.01% 2931

Other funds holding ORMP

AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management's ORMP Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Oramed Pharmaceuticals (ORMP) in Q2 2026: 229,882 shares worth $1.11M. The stake represents ﹤0.01% of the portfolio and ranks #2931 among its holdings.

57 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • Vanguard Portfolio Management held 229,882 shares of Oramed Pharmaceuticals worth $1.11M as of Q2 2026.
  • Oramed Pharmaceuticals was a new Vanguard Portfolio Management position in Q2 2026.
  • Oramed Pharmaceuticals made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2931 holding.
  • 57 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.